Our findings led to the conclusion that timely acting on this critical pathway was necessary for tumor (re)initiation, i.e., administering STAT3 inhibitors just as peri-surgical schedule (three administrations: at day −1, day of surgery, day +1), whereby we were able to efficiently suppress the occurrence of breast cancer local relapse [11]. The gene discussed is STAT3; the disease is breast carcinoma.